Mielóma multiplex: vizsgálatok itt: Japán
34 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Chiba, Fukushima, Iruma-gun, Kamogawa, Kashiwa-shi, Kita-ku, Kofu, Kumamoto, Kurume, Maebashi, Nagakute, Ōgaki, Sapporo, Sendai, Shibukawa, Shibuya-ku, Shiwa-gun, Suita-shi, Tokushima
- Életkor
- 18 év and over
- People
- 410 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00 - 3. fázisTaking peopleA Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Where
- Kofu, Matsumoto-shi, Nagoya, Okayama, Tokushima
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00 - 2. fázisTaking peopleA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Chiba, Fukuoka, Gifu, Hokkaido, Kobe, Koshigaya, Kumamoto, Kurashiki, Matsumoto, Okayama, Osaka, Ōtake, Shiwa-gun
- Életkor
- 18 év and over
- People
- 510 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00 - 4. fázisTaking peopleA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Where
- Nagoya, Shibuya City
- Életkor
- 18 év and over
- People
- 295 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00 - 3. fázisTaking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Bunkyō City, Chiba, Higashiibaraki-gun, Hirakata, Hyōgo, Iruma-gun, Kanagawa, Kanazawa, Kumamoto, Matsuyama, Nagasaki, Okayama, Osaka, Sapporo, Shibukawa, Shibuya-ku, Sunto-gun, Toyoake, Yamagata, Yamanashi
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - 1. fázisTaking peopleA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Where
- Shibuya City, Suita-shi, Tokyo
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00 - 3. fázisTaking peopleA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Bunkyō City, Chiba, Kamakura-shi, Kamogawa, Kofu, Minato, Shibuya City, Yokohama
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00 - 3. fázisTaking peopleA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Chiba, Fukuoka, Higashiibaraki, Hiroshima, Iruma, Kamakura, Kashiwa, Kitakyushu-shi, Koshigaya, Kumamoto, Nagaizumi-cho,Sunto-gun, Nagasaki, Sapporo, Shibuya-ku, Shiwa-gun Yahaba-cho, tabashi City, Tokyo
- Életkor
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085 - 1/2. fázisTaking peopleAZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Where
- Kashiwa, Nagoya, Yamagata
- Életkor
- 18 év and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06106945 · EU 2023-508590-89-00 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Fukuoka, Kanazawa, Kashiwa, Kumamoto, Nagoya, Nishinomiya, Okayama, Osaka, Shibuya-ku, Yamagata
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 3. fázisTaking peopleA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Fukuoka, Maebashi, Nagaizumi-chō, Okayama, Osaka, Sendai, Shibuya-ku, Yahaba-cho, Yamagata, Yoshida-gun
- Életkor
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00 - 1/2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Kyoto, Nagoya, Shibuya-ku, Suita-shi, Tokyo
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00 - 1/2. fázisTaking peoplePhase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Where
- Hidaka, Kasama-Shi, Kashiwa-shi, Kyoto, Maebashi, Nagoya, Shibuya-ku, Tokushima, Tokyo
- Életkor
- 18 év and over
- People
- 387 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03761108 · EU 2024-511454-45-00 - 3. fázisTaking peopleA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Nagoya
- Életkor
- 18 év to 130 év
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637 - 1. fázisTaking peopleA Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Aichi, Okayama, Tokyo, Yamagata
- Életkor
- 18 év and over
- People
- 186 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00 - 1. fázisTaking peopleA Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Where
- Bunkyo Ku, Koto-ku
- Életkor
- 18 év and over
- People
- 127 worldwide
- Run by
- AbbVie
See details and how to joinNCT07409246 - 1/2. fázisTaking peopleA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Where
- Kyoto, Nagoya, Shibuya-ku, Suita-shi
- Életkor
- 18 év to 64 év
- People
- 602 worldwide
- Run by
- AbbVie
See details and how to joinNCT06892522 · EU 2024-515770-27-00 - 2/3. fázisTaking peopleA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Where
- Isehara, Kurume-shi, Kyoto, Matsuyama, Nagoya
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- AbbVie
See details and how to joinNCT07095452 · EU 2025-520897-21-00 - 2. fázisCsak meghívásosInternational Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- Where
- Okayama
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- Sanofi
See details and how to joinNCT05669989 - 3. fázisTaking peopleCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Where
- Aichi, Ehime, Gunma, Hyōgo, Kyoto, Numakunai, Okayama, Osaka, Saitama, Shibuya-ku, Tokyo, Toyohashi, Yamagata
- Életkor
- 18 év and over
- People
- 380 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00 - 2. fázisTaking peopleStudy of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Chiba, Kyoto, Nagoya, Nishinomiya, Shibuya-ku
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06297226 - 3. fázisTaking peopleA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Where
- Bunkyō City, Kashiwa, Kyoto, Nagoya, Shibuya-ku, Shinjuku-ku
- Életkor
- 18 év and over
- People
- 508 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391657 - 3. fázisTaking peopleA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Chiba, Fukuoka, Gunma, Kamakura-shi, Kyoto, Matsuyama, Okayama, Sapporo, Tokyo, Yokohama
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07518186 - 2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- Where
- Aichi, Chiba, Ehime, Fukushima, Gunma, Hokkaido, Ishikawa, Numakunai, Okayama, Osaka, Sendai, Tokyo, Yamanashi
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07227311 · EU 2025-523117-28-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Akita, Fukuoka, Kagoshima, Kumamoto, Nagasaki, Nagoya, Okayama, Osaka, Sendai, Shibukawa, Shibuya-ku, Sunto-gun, Tokushima, Yahaba-cho, Yamagata, Yoshida-gun
- Életkor
- 18 év and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00